Discontinued psychiatric drugs in 2008

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1431-1443

  Kirchhoff, Victoria D ^b   Nguyen, Ha T T ^c   Soczynska, Joanna K ^c,d   Woldeyohannes, Hanna O ^c   McIntyre, Roger S ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Addiction; Anorectic; Antidepressants; Antipsychotics; Discontinued drugs; Mood stabilizers; Psychiatry

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ACP 104; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; BRAIN DERIVED GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CP 903397; DIANICLINE; DOV 216303; ELZASONAN; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; INSULIN; LIC 477 D; LICARBAZEPINE; LUAA 44608; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; NALTREXONE; NALUZOTAN; NEUROLEPTIC AGENT; NORCLOZAPINE; OCINAPLON; OLANZAPINE; ONO 2233 MS; ONO 2333 MS; OREX 003; OREX 004; OXCARBAZEPINE; PF 572778; PRX 23; PRX 90111; RIMONABANT; SSR 591813; SURINABANT; UNCLASSIFIED DRUG; VARENICLINE; ZONISAMIDE;

ALCOHOLISM; ANXIETY DISORDER; ARTHRALGIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG MECHANISM; FLU LIKE SYNDROME; FOCAL EPILEPSY; GASTROENTERITIS; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LIVER INJURY; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; NIGHTMARE; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OXIDATIVE STRESS; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; TOBACCO DEPENDENCE; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; TREATMENT FAILURE;

EID: 70349329592     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903184591     Document Type: Review

References (18)

1. Goldberg JF, Brooks JO III, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70(2):155-162
2. Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107(1):1-12
3. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. Am J Psychiatry 2009;166(5):599-607
4. Pharmaprojects Database, © Informa UK Ltd, 2009
5. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41 •• [2,3] Articles identified by the authors as being comprehensive contributions to the field.
6. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33(12):2922-2933
7. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54(3):317-329 (Pubitemid 37267861)
8. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996;57(10):470-484 (Pubitemid 26362312)
9. Knable MB, Torrey EF, Webster MJ, et al. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001;55(5):651-659
10. Iijima M, Chaki S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(3):622-627
11. Griebel G, Simiand J, Serradeil-Le GC, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002;99(9):6370-6375 (Pubitemid 34493318)
12. Souppart C, Gardin A, Greig G, et al. Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food.J Clin Pharmacol 2008;48(5):563-569
13. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002;27(1-2):121-130
14. Lippa A, Czobor P, Stark J, et al. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci USA 2005;102(20):7380-7385 (Pubitemid 40696386)
15. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4(3):281-285 (Pubitemid 351618774)
16. Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306(1):407-420 (Pubitemid 36734399)
17. Lamota L, Bermudez-Silva FJ, Marco EM, et al. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 2008;54(1):194-205 (Pubitemid 350299415)
18. Available from: www.clinicaltrials.gov